

References

I-159

1. O'Connor OA, Horwitz S, Masszi T, et al. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. *J Clin Oncol*. 2015;2492-2499.
2. Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. *BJH*. 2015;811-819.
3. Foss F, Duvic M, Lerner A, Waksman J, Whittaker S. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. *Clinical Lymphoma, Myeloma & Leukemia*. 2016;637-643.
4. Beleodaq (belinostat) for injection, for intravenous use [package insert]. Acrotech Biopharma, LLC. East Windsor, NJ. Revised 04/2022.
5. Istodax (romidepsin) for injection, for intravenous use [package insert]. Celgene Corp. Summit, NJ. Revised 07/2021.
6. Laribi K, Alani M, Truong C, and Baugier de Materre A. Recent advances in the treatment of peripheral T-cell lymphoma. *The Oncologist*. 2018;23:1039-1053.
7. Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balsler B, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. *Journal of Hematology & Oncology*. 2016;9(22):1-8.
8. Petrich A & Nabhan C. Use of class I histone deacetylase inhibitor romidepsin in combination regimens. *Leukemia & Lymphoma*. 2016;57(8):1755-1765.
9. National Comprehensive Cancer Network (NCCN). Belinostat. NCCN Drugs and Biologics Compendium®. 2022
10. National Comprehensive Cancer Network (NCCN). Romidepsin. NCCN Drugs and Biologics Compendium®. 2022
11. Micromedex DrugDex Compendium®. 2022.
12. Micromedex DrugDex Compendium®. 2022.
13. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Romidepsin.
14. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Belinostat.
15. Shustov A, Coiffier B, Horwitz S, et al. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. *Leukemia & Lymphoma*. 2017;58(10):2335-2341.
16. Allen PB, Lechowicz MJ. Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas. *Cancer Management & Research*. 2018;10:6731-6742.

17. Foss F, Horwitz S, Pro B, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. *Journal of Hematology & Oncology*. 2016;9:1-8.